NovaScan developed a novel, patented technology platform that detects, locates, and stratifies cancer in vivo or ex vivo, in seconds without capital equipment.
- Stage Prototype Ready
- Industry Medical Devices and Equipment
- Location Milwaukee, WI, USA
- Currency USD
- Founded January 2015
- Employees 6
- Incorporation Type C-corp
- Website novascaninc.com
NovaScan has developed a patented technology platform and products that detect many types of cancers. NovaScan products had 98+% sensitivity and specificity in more than 400 patients in breast and skin cancer detection. NovaScan also informs on cancer aggresiveness. The company's low cost products are small, simple to use, and provide real time response. First target is surgery for skin cancer; two JVs are signed for other types of cancer.
Craig has a long history in medtech, as an executive, a partner at a family office VC, a partner in Healthios, and as a strategy consultant.. Craig was a senior member GTCR backed team to roll up the urologic device space. He's an ex-partner at Healthios, an investment bank founded by ex-Baxter CEO Vern Loucks. Craig has MBA and MEng from Northwestern, and BSME from Wash U.
Dr. Gregory has spent more than twenty years researching the electrical properties of cells, and he both founded the company and developed much of NovaScan's core intellectual property. He holds numerous patents and is widely published. Previous to founding NovaScan. Bill was the Dean of the College of Engineering and Applied Science at UW-Milwaukee. Dr. Gregory obtained his Ph.D. from MIT and a BA from Georgetown, both in Physics.
Les is an experienced tech leader and manager of engineering teams. He has >20 years of R&D experience with a track record of bringing medical devices to market. He's held positions at Aksys Ltd, Optobionics, Welch Allyn, Zoll Medical and Endotronix. He teaches med device commercialization at University of Illinois at Chicago(UIC). Les has multiple medical device patents and is published in top journals. BS, MS and Ph.D. from UIC; MBA from DePaul
Dr. Link is an oncologist with deep experience in medical innovation. Dr Link was the CEO, CSO, Chairman and founder of NewLink Genetics, an immunotherapy company that discovered, developed and commercialized novel immuno-oncology product candidates. At its height, NewLink’s market cap was >$1.3B. He led the development of Merck’s EVERBO, the 1st FDA approved Ebola vaccine. His MD is from Stanford and he is an Air Force Academy graduate.